PON1 and Hepatic steatosis: Their pleiotropic effects include anti-inflammatory, anti-proliferation, antioxidant, anti-thrombotic, anti-cancer, and immune modulation, hence decreasing inflammation and fibrosis in NAFLD/NASH patients [10]. According to different studies, statins decrease hepatic steatosis by decreasing oxidative stress through increased hepatic antioxidant paraoxonase 1 (PON1) activity [11] and increase mitochondrial and peroxisomal oxidation and induction of peroxisomal proliferator-activated receptor alpha (PPARα), a fatty acid oxidation (FAO) regulator [12].